In these cases, the associated tumours show loss of the wildtype MBD4 allele and, like in neoplasms from individuals with MANS, showed elevated tumour mutation burden enriched in CpG > TpG mutations (signature SBS1/SBS96) [35, 93–96]. The gene discussed is MBD4; the disease is tumor predisposition syndrome 2.